LL-37 vs Thymosin Alpha-1
Updated 13 sources
Key differences
- 1LL-37 is innate defence that acts on microbes directly; thymosin alpha-1 works on T cells and adaptive immunity.
- 2Ta1 supports adaptive T-cell responses; LL-37 is an antimicrobial peptide of innate defence. Communities stack them.
Side by side
Facts from each record, in the same words as their own pages.
| LL-37 | Thymosin Alpha-1 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
13 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Regulatory4
- Zadaxin (thymalfasin) prescribing informationRxList, via a reference work · checked Oct 24, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risksFDA · checked Oct 24, 2026
- FDA signals potentially evolving stance toward compounding of certain peptidesGoodwin Procter, via a news report · checked Oct 24, 2026
- Pharmacy Compounding Advisory Committee, December 4, 2024 summary minutesFDA · checked Oct 24, 2026
Competitor guide8
- LL-37 profilepeptidesexplorer.com · checked Oct 24, 2026
- LL-37 research guidepeptidedeck.com · checked Oct 24, 2026
- LL-37 dosage guidebodyhackguide.co · checked Oct 24, 2026
- Thymosin Alpha-1 (TA1) guidepeptidedosingprotocols.com · checked Oct 24, 2026
Community-reported1
- Thymosin Alpha-1 community protocols and reportspeptideprotocolwiki.com, via a competitor guide · checked Oct 24, 2026